期刊： THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022; 13 ()
Background: Thrombocytopenia post hematopoietic stem-cell transplantation (HCT) usually contributes to poor outcomes with no standardized treatment. E......
期刊： THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022; 13 ()
Introduction: Multiple myeloma (MM) survival has greatly improved in recent decades. MM is usually diagnosed at a median age of 66-70 years. MM patien......
期刊： THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022; 13 ()
Background: Iron overload is one of the main factors that increase morbidity and mortality in patients with non-transfusion dependent thalassemia (NTD......
期刊： THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022; 13 ()
Background: The responses of intravenous immunoglobulin (IVIg) or corticosteroids as the initial treatment on pregnancy with ITP were unsatisfactory. ......
期刊： THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022; 13 ()
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, hematologic disease characterized by complement-mediated hemolysis, thrombosis, and var......
期刊： THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022; 13 ()
Purpose: Graft-versus-host disease (GVHD) is an important complication after human leukocyte antigen (HLA) haploidentical donor (HID) hematopoietic st......
期刊： THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022; 13 ()
Background: Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) based on granulocyte colony-stimulating factor plus anti-thymocyte reg......
期刊： THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022; 13 ()
Introduction: Bortezomib has been reported to favourably impact the outcomes of t(4;14) and del(17p) in multiple myeloma (MM), but its impact on gain ......
期刊： THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022; 13 ()
MYD88/CD79B-mutated (MCD) genotype is a genetic subgroup of diffuse large B-cell lymphoma (DLBCL) with the co-occurrence of MYD88(L265P) and CD79B mut......
期刊： THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021; 12 ()
Background: DDX41 serves as a DNA sensor in innate immunity and mutated DDX41 is pathogenic, mainly for myeloid neoplasms. Methods: In this study, "DD......
期刊： THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021; 12 ()
Background: Currently, the goal of chronic myeloid leukemia (CML) treatment is normal survival and good quality of life without life-long treatment, n......
期刊： THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021; 12 ()
Daratumumab is a humanized anti-CD38 IgG1 monoclonal antibody which could be used for multiple myeloma (MM). MM with plasma-cell leukemia (PCL) transf......
期刊： THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021; 12 ()
Background and aims: Monoclonal immunoglobulin light chain associated Fanconi syndrome (LC-FS) is a rare disease that involves proximal tubules. As mo......
期刊： THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021; 12 ()
Some subtypes of acute myeloid leukemia (AML) share morphologic, immunophenotypic, and clinical features of acute promyelocytic leukemia (APL), but la......
期刊： THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020; 11 ()
Nucleophosmin (NPM1) is an abundant nucleolar protein that is implicated in a variety of biological processes and in the pathogenesis of several human......
